2025
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial
Singh S, Nguyen J, Fudman D, Gerich M, Shah S, Hudesman D, McConnell R, Lukin D, Flynn A, Hwang C, Sprung B, Gaidos J, Mattar M, Rubin D, Hashash J, Metwally M, Ali T, Ma C, Hoentjen F, Narula N, Bessissow T, Rosenfeld G, McCurdy J, Ananthakrishnan A, Cross R, Gaytan J, Gurrola E, Patel S, Siegel C, Melmed G, Weaver S, Power S, Zou G, Jairath V, Hou J. Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterology 2025, 12: e001615. PMID: 40164445, PMCID: PMC11962770, DOI: 10.1136/bmjgast-2024-001615.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseAdvanced therapiesTreat-to-targetSymptomatic remissionBowel inflammationOpen-labelAsymptomatic patientsPatient-Centered Outcomes Research InstituteBowel diseaseControlled TrialsSafety of switchingClinical practiceActive bowel inflammationReduced bowel inflammationDeep remissionEndoscopic remissionTreatment failurePrimary endpointRandomised controlled trialsTargeted immunomodulationRemissionTherapyPatientsGood clinical practiceInformed consent
2018
Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia
Huang J, Liu C, Hwang T, Chen Y, Hsu Y, Hwu H, Lin Y, Hsieh M, Liu C, Chien Y, Tseng W. Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia. Human Brain Mapping 2018, 39: 2007-2019. PMID: 29377322, PMCID: PMC6866389, DOI: 10.1002/hbm.23982.Peer-Reviewed Original ResearchConceptsGeneralized fractional anisotropyGeneralized fractional anisotropy valuesAdequate antipsychotic treatmentNegative symptom scoresNonremission groupWhite matter tract integrityWhite matter integrityHealthy controlsRemission stateWhite matter tract bundlesWhite matter tractsReduced integrationAntipsychotic treatmentNonremitted patientsSchizophrenia patientsSymptomatic remissionIllness durationAnalysis of covarianceSchizophreniaDiffusion spectrum imagingTract integrityPost Hoc AnalysisFractional anisotropyMedication dosesEducation years
2016
Cross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, Cannon TD, Krystal JH, Corlett PR. Cross-trial prediction of treatment outcome in depression: a machine learning approach. The Lancet Psychiatry 2016, 3: 243-250. PMID: 26803397, DOI: 10.1016/s2215-0366(15)00471-x.Peer-Reviewed Original ResearchConceptsTreatment outcomesTreatment groupsEscitalopram treatment groupSpecific antidepressantsPatient-reported dataSequenced Treatment AlternativesClinical trial dataIndependent clinical trialsClinical remissionSymptomatic remissionClinical trialsTreatment efficacyPatientsProspective identificationTreatment alternativesTrial dataDepressionRemissionAntidepressantsOutcomesGroupLevel 1CitalopramCohortClinicians
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply